**Perioperative Management of Well-Differentiated Thyroid Carcinoma**

**Evidence-Based Guideline**

**Definition:** Well-differentiated thyroid cancer includes both papillary and follicular thyroid carcinomas.

**Epidemiology:** The SEER Cancer Statistics reported an incidence of 3.2 per 100,000 for 15-19 year olds, increasing from previous years. (1) Papillary thyroid carcinoma is the most common malignancy of the thyroid gland in children. (2) Follicular thyroid cancer is uncommon, with medullary thyroid cancer, poorly differentiated tumors, and frankly undifferentiated (anaplastic) thyroid carcinomas are rare in young patients. (3)

**Inclusion Criteria**
- Birth-25 years of age;
- Fine needle aspiration (FNA) biopsy proven well-differentiated thyroid carcinoma (papillary or follicular);
- No clinical or ultrasound evidence of loco-regional metastatic disease

**Exclusion Criteria**
- >25 year of age, well differentiated thyroid carcinoma with known loco-regional metastatic disease;
- Medullary or anaplastic thyroid carcinoma
- Pregnancy

**Diagnostic Evaluation**

**History: Assess for**
- Prior radiation exposure
- Genetic syndromes

**Physical Examination**
- Visual examination and palpation of the thyroid

**Laboratory Tests**
- Thyroid function screen (T4 and TSH)
- Thyroglobulin panel
- Thyroid antibodies

**Diagnostic Imaging**
- Ultrasonography of the thyroid with fine needle aspiration

**Surgical Planning**

**Referral**
- Thyroid Tumor Board
- Pediatric surgery or Otolaryngology

**Laboratory Tests**
- Calcium
- Phosphorous
- Magnesium
- PTH
- Albumin
- Vitamin D 25 Hydroxy

**Diagnostic Imaging**
- Lymph node mapping if concern for regional disease

---

**Critical Points of Evidence**

**Evidence Supports**
- To complete initial lymph node mapping with ultrasound pre-operatively to evaluate for regional disease. (4-16) – Strong recommendation, low quality evidence
- To evaluate the patient for pre-existing vitamin D deficiency prior to surgery and treat any deficiencies. (17-24) – Strong recommendation, very low quality evidence
- To check postoperative parathyroid hormone and calcium levels to evaluate for hypoparathyroidism and hypocalcemia. (25-27)
  - Strong recommendation, low quality evidence
- To administer post-operative oral calcium supplementation to patients post-thyroidectomy to avoid transient hypocalcemia. (28-30)
  - Strong recommendation, moderate quality evidence

**Evidence Against**
- The routine use of computed tomography to evaluate for regional disease for pre-thyroidectomy evaluation. (4-16) – Strong recommendation, low quality evidence
- Prophylactic central neck dissection in patients with papillary thyroid carcinoma and no loco-regional metastases. (31-39) – Strong recommendation, moderate quality evidence
- The use of pre-operative calcium supplementation. (30,40) – Strong recommendation, very low quality evidence

**Evidence Lacking/Inconclusive**
- The use of intermittent recurrent nerve monitoring during surgery to reduce incidence of nerve injury. (41) – Unable to make a recommendation

*NOTE: The references cited represent the entire body of evidence reviewed to make each recommendation.*
Condition-Specific Elements of Clinical Management

**Admission Criteria**
- Admit for post-thyroidectomy care

**Discharge Criteria**
Patient can go home on calcium carbonate BID and calcitrol daily on postop if the patient has no hypocalcemia symptoms, no calcium level <8.5 during hospitalization, and an intra-op PTH >30.

**Consults/Referrals**
Endocrinology to follow and order weekly labs to wean calcium and calcitriol supplementation and manage thyroid hormone replacement therapy.

**Follow-Up Care**
- Thyroid replacement: Liothyronine
  - Age <10 years: 25 mcg daily
  - Age ≥10 years: 50 mcg daily

**Parent/Caregiver Teaching**
- Signs and symptoms of hypocalcemia: perioral and acral paresthesias, stiffness, clumsiness, myalgias, muscle spasms, diaphoresis, seizures.

**Measures**

**Process**
- Central and lateral neck dissections
- Use of recurrent nerve monitoring
- Post-operative laryngoscopy
- Readmissions or emergency center visits
- Returns to OR

**Outcome**
- Post-op transient hypocalcemia during hospitalization
- Rates of IV calcium use during hospitalization
- Patients requiring calcium supplementation at 6 months and 1 year post-op
- Recurrent laryngeal nerve injury
Texas Children’s Hospital Evidence-Based Outcomes Center
Perioperative Management of Well-Differentiated Thyroid Carcinoma Algorithm

Exclusion Criteria
- >25 year of age
- Well differentiated thyroid carcinoma with known loco-regional metastatic disease
- Medullary or anaplastic thyroid carcinoma
- Pregnancy.

Begin

Suspected Thyroid Carcinoma?

No

Manage as appropriate to clinical findings (OFF Algorithm)

Yes

Manage as appropriate to clinical findings (OFF Algorithm)

Neck lymphadenopathy on exam?

No

Manage as appropriate to clinical findings (OFF Algorithm)

Yes

Initial Assessment

Labs: T4, Tg Panel, Thyroid Antibodies, Imaging: US + Fine Needle Aspiration (FNA)

Referral: Endocrinology

FNA confirmed well differentiated thyroid carcinoma

No

Manage as appropriate to clinical findings (OFF Algorithm)

Yes

Pre-op Assessment & Surgical Planning

Labs: 25-OH vitamin D levels, Ca, Ph, Mg, PTH, albumin

Medications: If vitamin D <30 ng/mL, start 2,000 IU daily, if vit D >20, start 4000 IU daily or 50,000 IU weekly.

Imaging: Lymph node mapping with or without lymph node biopsy

Pre-Op Visit: Pad Surgery or Otolaryngology

Referral: Oncology

Day of Surgery

Draw calcium and PTH pre-incision

Total Thyroidectomy without central neck dissection

Central neck metastases identified during surgery?

Yes

Consider central neck dissection (OFF Algorithm)

No

Post-op Care

Labs: PTH and total calcium drawn in PACU, then calcium Q6 hours

Physical Exam: Assess for Hypocalcemia

Medications: Give both calcium CARbonate and calcitriol 0.5 mcg in PACU. Order calcium CARbonate q8 hours and calcitriol 0.5 mcg once daily (MAX 2 mcg per day).

See calcium CARbonate dosing below.

Calcium abnormal?

No

Assess patient and evaluate symptoms

Calcium 7-8 mg/dL

Re-check Ca, Mg, Phos, PTH by venipuncture.

If Symptomatic: Provider at bedside. Start IV calcium GLUConate 100 mg/kg dosed (MAX 3000 mg per dose), administer in large vein over 5-10 minutes.

If Asymptomatic: Increase oral calcium CARbonate by 100% and increase calcitriol to BID with dose of each given NGW, consider IV

Calcium >10 mg/dL

Decrease oral calcium CARbonate dose by 50%

Calcium 4.5-7 mg/dL

Assess patient and evaluate symptoms

Calcium 2.5-4.5 mg/dL

Re-check Ca, Mg, Phos, PTH by venipuncture and notify provider on call for surgery. If unable to contact, escalate to Endocrine fellow on call.

Increase oral calcium dose by 30% and calcitriol to twice daily.

Calcium <2.5 mg/dL

Consider central neck dissection (OFF Algorithm)

Post-operative Calcium CARbonate Dosing

<table>
<thead>
<tr>
<th>Weight</th>
<th>Calcium CARbonate Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>10-20 kg</td>
<td>250 mg</td>
</tr>
<tr>
<td>21-40 kg</td>
<td>750 mg</td>
</tr>
<tr>
<td>&gt;41 kg</td>
<td>1,000 mg</td>
</tr>
<tr>
<td>&gt;50 kg</td>
<td>1,500 mg</td>
</tr>
</tbody>
</table>

Available Preparations: Suspension 250 mg/mL; Tablet 500 mg

© Evidence-Based Outcomes Center
Texas Children’s Hospital
References


Clinical Standards Preparation
This clinical standard was prepared by the Evidence-Based Outcomes Center (EBOC) team in collaboration with content experts at Texas Children's Hospital. Development of this clinical standard supports the TCH Quality and Patient Safety Program initiative to promote clinical standards and outcomes that build a culture of quality and safety within the organization.

Perioperative Management of Well-Differentiated Thyroid Carcinoma Content Expert Team
Sadam Abbas, MSN, MBA, RN—Nursing-Outpatient Endocrinology
Jennifer Abernathy, RN—Nursing-Outpatient Endocrinology
Akudo Anyanwu, RN—Nursing-Outpatient Oncology
Ioanna Athanassaki, MD—Endocrinology
Charlene Barclay, RN—Clinical Data Specialist, Outcomes and Impact Service
Daniel Chelius, MD—Otolaryngology
Murali Chintagumpala, MD—Oncology
Annalyn DeMello, RN—Pediatric Surgery
Sarah Gammons, MD—Endocrinology
Jose Hernandez, MD—Radiology
Camlesh Kukreja, MD—Radiology
Monica Lopez, MD—Pediatric Surgery
Priya Mahajan, MD—Oncology
Nadia Mahmood, MD—Radiology
Nadia Merchant, MD—Endocrinology
Robert Orth, MD, PhD—Radiology
John Poston, PhD—Radiation Safety Officer
Norma Quintanilla, MD—Pathology
Victor Seghers, MD, PhD—Radiology
Andrew Sher, MD—Radiology
Matthew Sitton, MD—Otolaryngology
Rajkumar Venkatramani, MD—Oncology
Adam Vogel, MD—Pediatric Surgery
David Wesson, MD—Pediatric Surgery

Clinical standard developed through the Evidence Based Outcomes Center (EBOC).

No relevant financial or intellectual conflicts to report.

Development Process
This clinical standard was developed using the process outlined in the EBOC Manual. The literature appraisal documents the following steps:

1. Review Preparation
   - PICO questions established
   - Evidence search confirmed with content experts
2. Review of Existing External Guidelines
   - NCCN Guidelines: Thyroid Carcinoma by the National Comprehensive Cancer Network (2016)
   - Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer by the American Thyroid Association Guidelines Task Force on Pediatric Thyroid Cancer (2015)
   - Guidelines for the Management of Thyroid Cancer by the British Thyroid Association (2014)
   - Thyroid Carcinoma by the American College of Radiology (2013)
   - Thyroid Cancer: EMSO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-Up by the European Society for Medical Oncology (2012).
3. Literature Review of Relevant Evidence
   - Searched: PubMed, Cochrane, AHRQ, National Institute for Clinical Excellence, Google Scholar
4. Critically Analyze the Evidence

© Evidence-Based Outcomes Center
Texas Children's Hospital

- Nine of meta-analyses, two randomized controlled trials, and twenty-seven nonrandomized studies.

5. Summarize the Evidence
   - Materials used in the development of the clinical standard, literature appraisal, and any order sets are maintained in a Perioperative Management of Well-Differentiated Thyroid Carcinoma evidence-based review manual within EBOC.

Evaluating the Quality of the Evidence
Published clinical guidelines were evaluated for this review using the AGREE II criteria. The summary of these guidelines are included in the literature appraisal: AGREE II criteria evaluate Guideline Scope and Purpose, Stakeholder Involvement, Rigor of Development, Clarity and Presentation, Applicability, and Editorial Independence using a 4-point Likert scale. The higher the score, the more comprehensive the guideline.

This clinical standard specifically summarizes the evidence in support of or against specific interventions and identifies where evidence is lacking/inconclusive. The following categories describe how research findings provide support for treatment interventions. “Evidence Supports” provides evidence to support an intervention “Evidence Against” provides evidence against an intervention. “Evidence Lacking/Inconclusive” indicates there is insufficient evidence to support or refute an intervention and no conclusion can be drawn from the evidence.

The GRADE criteria were utilized to evaluate the body of evidence used to make practice recommendations. The table below defines how the quality of the evidence is rated and how a strong versus weak recommendation is established. The literature appraisal reflects the critical points of evidence.

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>STRONG</th>
<th>WEAK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality Type of Evidence</td>
<td>Desirable effects clearly outweigh undesirable effects or vice versa</td>
<td>Desirable effects closely balanced with undesirable effects</td>
</tr>
<tr>
<td>High</td>
<td>Consistent evidence from well-performed RCTs or exceptionally strong evidence from unbiased observational studies</td>
<td>Evidence from RCTs with important limitations (e.g., inconsistent results, methodological flaws, indirect evidence, or imprecise results) or unusually strong evidence from unbiased observational studies</td>
</tr>
<tr>
<td>Moderate</td>
<td>Evidence for at least 1 critical outcome from observational studies, RCTs with serious flaws or indirect evidence</td>
<td>Evidence for at least 1 critical outcome from unsystematic clinical observations or very indirect evidence</td>
</tr>
<tr>
<td>Low</td>
<td>Evidence for at least 1 critical outcome from unsystematic clinical observations or very indirect evidence</td>
<td></td>
</tr>
<tr>
<td>Very Low</td>
<td>Evidence for at least 1 critical outcome from unsystematic clinical observations or very indirect evidence</td>
<td></td>
</tr>
</tbody>
</table>

Recommendations
Practice recommendations were directed by the existing evidence and consensus amongst the content experts. Patient and family preferences were included when possible. The Content Expert Team and EBOC team remain aware of the controversies in the management of well-differentiated thyroid carcinoma in children. When evidence is lacking, options in care are provided in the clinical standard and the accompanying order sets (if applicable).

Approval Process
Clinical standards are reviewed and approved by hospital committees as deemed appropriate for its intended use. Clinical standards are reviewed as necessary within EBOC at Texas Children's Hospital. Content Expert Teams are involved with every review and update.
**Disclaimer**
Practice recommendations are based upon the evidence available at the time the clinical standard was developed. Clinical standards (guidelines, summaries, or pathways) do not set out the standard of care and are not intended to be used to dictate a course of care. Each physician/practitioner must use his or her independent judgment in the management of any specific patient and is responsible, in consultation with the patient and/or the patient’s family, to make the ultimate judgment regarding care.

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 2018</td>
<td>Originally Completed</td>
<td></td>
</tr>
<tr>
<td>April 2023</td>
<td>Reaffirmed</td>
<td></td>
</tr>
</tbody>
</table>